DPL: Packaging Cell Line For Diphtheria Toxin Expressing Non-replicating Adenovirus
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cancer (suicide gene therapy); immunotoxin production
Modality
Gene Therapy
Mechanism
diphtheria toxin-expressing adenovirus packaging cell line
Target
—
rNPV Envelope
Low
-$15.7M
costs +25% · peak −25%
Base
-$12.5M
cumulative PoS 0.6%
High
-$9.3M
costs −25% · peak +25%
This is an illustrative adenoviral-toxin product envelope only because the cohort pipeline expects stages. The actual asset is a packaging cell line with an expired patent, so PoS and costs should not be read as a product development plan.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #45 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#8) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
DPL diphtheria-toxin adenovirus packaging cell line
The direct asset: a cell line for producing diphtheria-toxin-expressing non-replicating adenovirus and immunotoxins. It is a manufacturing/research tool, not a therapeutic candidate.
Criteria 1: exact asset reality; no product comparator should override this.
Oncorine / H101 - oncolytic adenovirus
Approved adenovirus-virotherapy archetype showing that adenoviral cancer products can reach market in limited settings. It is not a DT packaging-cell-line comparator.
Criteria 3 and 4: regulatory/modality archetype only; not a product comparator.
Diphtheria-toxin adenoviral cancer constructs
Adjacent preclinical archetype for using adenoviral vectors to deliver attenuated diphtheria toxin. Supports the manufacturing-tool context but not a standalone JHTV drug story.
Criteria 1 and 4: same toxin/vector idea, preclinical and adjacent only.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $5.0M | 18 mo | 24.0% | [0] [2] |
| Phase I | $20.0M | 18 mo | 48.0% | [1] [2] |
| Phase II | $60.0M | 30 mo | 18.0% | [1] [2] |
| Phase III | $150.0M | 42 mo | 34.0% | [1] |
| NDA/BLA Review | $10.0M | 12 mo | 80.0% | [1] |
Multiplier handling: No multipliers eligible for this asset under the locked methodology. See methodology for the rule.
Peak revenue and discount rate
$25.0M peak · WACC 16.0%
Peak revenue. A packaging cell line should be valued through tool licensing, service revenue, or research support, not full product peak. The $25M illustrative figure is a conservative placeholder for possible licensing/tool value and not a drug forecast.
WACC. A non-commercial research/manufacturing tool with expired IP has high uncertainty and little standalone equity value.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$12.5M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$57.1M
P25
-$11.7M
P50 (median)
-$4.9M
P75
-$3.1M
P95
-$1.9M
Prob ≥ 0
0.0%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is a packaging cell line / research tool cmo_findings.asset_class_reality | DPL: Packaging Cell Line For Diphtheria Toxin Expressing Non-replicating Adenovirus regulatory | 2017-02-24 | high |
Adenoviral cancer-product archetype comparators[1] | Oncorine, the World First Oncolytic Virus Medicine and its Update in China peer_review | 2017-11-01 | high |
Oncolytic adenovirus field remains specialized stage_profile.phase_3.pos | Concepts in Oncolytic Adenovirus Therapy peer_review | 2021-09-26 | high |
Diphtheria-toxin adenoviral constructs are preclinical-adjacent comparators[2] | The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells peer_review | 2020-12-01 | medium |
Thesis
Why this asset earns its rank
This is unambiguously a research/manufacturing tool, not a therapeutic asset. The JHU page describes a packaging cell line for producing diphtheria-toxin-expressing non-replicating adenovirus and immunotoxins, and the patent is expired. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial.
Comparator economics reinforce the non-commercial framing. Oncorine shows adenoviral virotherapy can reach market in narrow settings, and diphtheria-toxin adenoviral constructs support the tool's technical context, but neither makes the DPL cell line a drug product. The engine result is -$15.7M to -$9.3M, with a base rNPV of -$12.5M and cumulative PoS of 0.6%; that placeholder should be read as a conservative tool/licensing envelope, not a cancer-therapy forecast.
Verdict: the honest answer is the defensible answer. This entry earns its rank from the rubric's gene-therapy bucket and broad clinical relevance, but a CMO would immediately reject any full DCF built around a packaging cell line.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: the asset is a packaging cell line and production method, not a clinical adenovirus therapy.
- Expired IP: the listed US patent expired in 2023, sharply limiting exclusivity and licensing leverage.
- Manufacturing-tool value capture: any economics would be service/tool licensing, not ownership of downstream adenoviral or immunotoxin products.
- Safety/regulatory risk belongs to downstream toxin-vector products, not to the cell line itself.